CYTOKINETICS INCORPOR

Cytokinetics to Announce Second Quarter Results on August 8, 2024

25 يوليو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Seven Upcoming Presentations at the European Society of Cardiology Congress 2024

16 يوليو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

03 يوليو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants

17 يونيو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 يونيو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Cytokinetics to Participate in June Investor Conferences

29 مايو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Closing of Public Offering of Common Stock

28 مايو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Pricing of Public Offering of Common Stock

22 مايو 2024 23:30:50 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Proposed Public Offering of Common Stock

22 مايو 2024 16:02:00 بحسب Nasdaq GlobeNewswire

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

22 مايو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology

17 مايو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024

15 مايو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress

13 مايو 2024 09:33:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine

13 مايو 2024 09:33:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Reports First Quarter 2024 Financial Results

08 مايو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586

08 مايو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

08 مايو 2024 07:30:00 بحسب Nasdaq GlobeNewswire

Cytokinetics to Hold Annual Meeting of Stockholders

07 مايو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 مايو 2024 16:00:00 بحسب Nasdaq GlobeNewswire

Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress

29 أبريل 2024 16:00:00 بحسب Nasdaq GlobeNewswire